Saturday, December 11, 2021 10:08:36 PM
The last one is interesting to think about in the new world. Do we really ever need comparison studies in ndGBM? Now you need to prove your salt first in recurrent GBM, notice the recent companies path for new products, and if you do you may be allowed some day after a lot of long term experience you may be able to challenge DCVax. But not before then because Linda took us out very far to prove a point which will be very hard for others now to prove.
If you are all comparing to the same randomly captured, matched database that gets close to a defacto comparison.
Even when you do break rules they usually start small and get bigger and bigger if you just wont learn your lsson or you step way out of line. Premarket promoting a drug in review gives the market the impression the drug has been approved when it has not. Think about a drug with other indications, that could be downright dangerous. They try to be consistent too unless that is not really good for patients.
That is why you can only do it with their permission, a permission they don’t always grant. They too are interested in getting real advances in the bodies of patients as quickly as possible and a little ‘coming soon’ helps when you are pushing to get across a finish line where the race has already been called. Now lets say you are trying to remain stealth about it, then you choose the first path rather than the obvious second path by actually saying ‘coming soon.’. They give you a choice but you can’t do both or too much and they are watching. If you make innocent mistakes anytime, they handle you softly. But they do stop you.
That is the real value of the tote that gets mocked…it is rather stealthy and one that could just get a stinging slap. But the full page add is more and complete, because of that, the tote is confirmation of no slappy slappy has gone on.
It is only a tote…are you serious? Yes, quite serious actually because it came second.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
FEATURED Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • Mar 16, 2026 8:37 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
